Figure 4From: Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/mlFour-year biochemical relapse-free survival in patients with prostate specific-antigen doubling time (PSADT) ≥ 7 months and that in patients with PSADT < 7 months.Back to article page